Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits

Up to 20% of all newly diagnosed breast cancers are non-invasive carcinomas, known as ductal carcinoma in situ.1 Surgical excision is the mainstay of management, with the addition of breast irradiation after breast-conserving surgery shown to reduce ipsilateral breast cancer recurrence in five randomised controlled trials.1 Because molecular and epigenetic evidence suggests that ductal carcinoma in situ is a precursor for invasive breast cancer, an important question has been whether systemic adjuvant endocrine therapy can affect the natural history of ductal carcinoma in situ, especially given its role in reducing recurrence and preventing contralateral disease and improving overall survival in patients with oestrogen-receptor (ER) positive invasive breast cancer.

email